Physician profile
Brooke Williams
NPI 1003356122
$3,682.29
in general payments reported to CMS, 2019-2025
25 companies · $714 in 2025
The $714 reported for 2025 was more than what 93% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19.33 · 2020: $101 · 2021: $567 · 2022: $858 · 2023: $837 · 2024: $585 · 2025: $714.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,136.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,136.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $797.44 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $666.67 | 2021-2025 | |
| Abbvie INC. | $297.14 | 2023-2025 | Dalvance, Teflaro, Avycaz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $232.10 | 2021-2024 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Novo Nordisk INC | $225.07 | 2022-2023 | Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $205.70 | 2020-2025 | Zerbaxa, Dificid, Recarbrio |
| Astrazeneca Pharmaceuticals LP | $167.17 | 2020-2024 | Andexxa, Farxiga |
| Gilead Sciences, INC. | $129.70 | 2021-2022 | |
| Glaxosmithkline, LLC. | $117.05 | 2023 | |
| Amarin Pharma, INC. | $105.03 | 2023 | |
| Alexion Pharmaceuticals, INC. | $101.53 | 2019-2025 | Ultomiris |
| Janssen Pharmaceuticals, INC | $97.66 | 2020-2024 | Xarelto |
| Avanos Medical | $88.60 | 2023 | Pnb and Accessories |
| E.R. Squibb & Sons, L.L.C. | $80.19 | 2021-2025 | Eliquis, Camzyos |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $73.57 | 2022-2025 | Xifaxan |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $70.86 | 2025 | |
| Paratek Pharmaceuticals, INC. | $40.07 | 2022-2023 | Nuzyra |
| Smith+Nephew, INC. | $38.76 | 2025 | Collagenase Santyl |
| Cvrx, INC. | $29.72 | 2022 | |
| Galderma Laboratories, L.P. | $26.50 | 2022 | |
| Abbott Laboratories | $23.47 | 2024 | Mitraclip |
| Heron Therapeutics, INC. | $19.70 | 2025 | Zynrelef |
| Takeda Pharmaceuticals U.S.A., INC. | $17.98 | 2025 | Glassia |
| Boston Scientific Corporation | $16.32 | 2020 | |
| Philips North America LLC | $14.29 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brooke Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.